Mraz Amerine & Associates Inc. increased its position in Amgen Inc. (NASDAQ:AMGN) by 0.0% during the second quarter, Holdings Channel reports. The fund owned 5,707 shares of the medical research company’s stock after buying an additional 1 shares during the period. Mraz Amerine & Associates Inc.’s holdings in Amgen were worth $868,000 at the end of the most recent reporting period.
A number of other institutional investors have also added to or reduced their stakes in the company. Oakworth Capital Inc. increased its position in Amgen by 16.6% in the second quarter. Oakworth Capital Inc. now owns 701 shares of the medical research company’s stock worth $111,000 after buying an additional 100 shares in the last quarter. Delta Asset Management LLC TN increased its position in Amgen by 9.1% in the second quarter. Delta Asset Management LLC TN now owns 1,020 shares of the medical research company’s stock worth $155,000 after buying an additional 85 shares in the last quarter. Capital Advisors Ltd. LLC increased its position in Amgen by 0.6% in the second quarter. Capital Advisors Ltd. LLC now owns 1,078 shares of the medical research company’s stock worth $164,000 after buying an additional 6 shares in the last quarter. Vigilant Capital Management LLC increased its position in Amgen by 2.6% in the second quarter. Vigilant Capital Management LLC now owns 1,283 shares of the medical research company’s stock worth $195,000 after buying an additional 33 shares in the last quarter. Finally, Evanson Asset Management LLC acquired a new position in Amgen during the second quarter worth approximately $211,000. 79.15% of the stock is owned by hedge funds and other institutional investors.
Shares of Amgen Inc. (NASDAQ:AMGN) traded up 0.36% during trading on Friday, reaching $167.50. The company had a trading volume of 1,679,823 shares. The company has a 50 day moving average of $170.75 and a 200-day moving average of $161.82. Amgen Inc. has a 52-week low of $139.02 and a 52-week high of $176.85. The firm has a market capitalization of $125.35 billion, a P/E ratio of 17.14 and a beta of 0.94.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Wednesday, July 27th. The medical research company reported $2.84 earnings per share for the quarter, beating analysts’ consensus estimates of $2.74 by $0.10. Amgen had a return on equity of 29.30% and a net margin of 33.07%. The firm had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.58 billion. During the same period in the prior year, the business posted $2.57 earnings per share. The business’s revenue was up 5.9% compared to the same quarter last year. Equities analysts expect that Amgen Inc. will post $11.35 earnings per share for the current year.
The business also recently declared a quarterly dividend, which was paid on Thursday, September 8th. Shareholders of record on Wednesday, August 17th were given a $1.00 dividend. This represents a $4.00 dividend on an annualized basis and a yield of 2.39%. The ex-dividend date was Monday, August 15th. Amgen’s dividend payout ratio (DPR) is 40.90%.
AMGN has been the subject of a number of research reports. Goldman Sachs Group Inc. reaffirmed a “buy” rating and issued a $202.00 price objective on shares of Amgen in a report on Wednesday, June 15th. Vetr raised shares of Amgen from a “hold” rating to a “buy” rating and set a $159.50 price objective for the company in a report on Monday, June 13th. Zacks Investment Research raised shares of Amgen from a “hold” rating to a “buy” rating and set a $166.00 price objective for the company in a report on Wednesday, June 29th. Jefferies Group reiterated a “buy” rating and issued a $187.00 target price on shares of Amgen in a research note on Wednesday, July 13th. Finally, BMO Capital Markets reiterated a “buy” rating and issued a $186.00 target price on shares of Amgen in a research note on Tuesday, July 12th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and twelve have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $184.94.
In other Amgen news, VP Annette Louise Such sold 3,000 shares of the company’s stock in a transaction on Tuesday, August 2nd. The stock was sold at an average price of $174.59, for a total value of $523,770.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.20% of the stock is owned by company insiders.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).